object
object
evalu
whether
vaccin
pneumococc
conjug
vaccin
prevent
incid
communityacquir
pneumonia
cap
caus
influenza
influenzaassoci
cap
iacap
respiratori
virus
elderli
method
analysi
part
communityacquir
pneumonia
immun
trial
adult
capita
doubl
blind
random
placebocontrol
trial
immunocompet
individu
age
year
cap
defin
clinic
radiolog
criteria
oropharyng
swab
collect
individu
refer
sentinel
centr
clinic
suspicion
pneumonia
presenc
influenza
b
parainfluenza
human
adeno
boca
corona
metapneumo
rhinoand
respiratori
syncyti
virus
determin
realtim
pcr
result
episod
suspect
pneumonia
viral
aetiolog
test
proport
influenza
viru
human
metapneumoviru
respiratori
syncyti
viru
respect
oropharyng
swab
pcr
test
avail
episod
fulfil
criteria
cap
yield
first
episod
iacap
placebo
groupdvaccin
efficaci
iacap
ci
p
annual
influenza
vaccin
receiv
group
placebo
group
confirm
cap
case
conclus
random
studi
elderli
individu
high
uptak
influenza
vaccin
associ
statist
signific
reduct
influenza
virusassoci
cap
overal
incid
noninfluenza
viral
pneumonia
low
sm
huijt
clin
microbiol
infect
associ
infect
influenza
viru
streptococcu
pneumonia
describ
first
time
influenza
pandem
subsequ
studi
confirm
relat
incid
invas
pneumococc
diseas
respiratori
viru
infect
moreov
anim
studi
demonstr
pathogen
synergi
influenza
viru
pneumonia
transmiss
acquisit
pneumonia
enhanc
influenza
viru
infect
howev
exact
mechan
underli
observ
remain
elucid
pneumococc
conjug
vaccin
pcv
effect
prevent
invas
pneumococc
diseas
communityacquir
pneumonia
cap
otiti
media
children
vaccin
type
pneumococc
cap
invas
pneumococc
diseas
elderli
african
childrendwith
without
human
immunodefici
viru
infectiondth
nineval
pcv
reduc
occurr
pneumonia
hospit
associ
influenza
viru
investig
virus
influenza
b
viru
parainfluenza
viru
adenoviru
respiratori
syncyti
viru
ci
ci
respect
illustr
import
pneumonia
superinfect
virusassoci
pneumonia
children
whether
pcv
similar
effect
virusassoci
cap
adult
unknown
within
communityacquir
pneumonia
immun
trial
adult
capita
evalu
efficaci
pcv
vaccin
prevent
first
episod
influenzaassoci
cap
iacap
preval
human
virus
parainfluenza
virus
adenoviru
coronaviru
bocaviru
metapneumoviru
respiratori
syncyti
viru
rhinoviru
elderli
patient
cap
furthermor
proport
iacap
evalu
year
season
coverag
influenza
vaccin
among
patient
cap
determin
current
studi
prespecifi
exploratori
object
capitatri
communitydwel
immunocompet
individu
year
older
randomli
assign
receiv
placebo
vaccin
design
studi
main
result
describ
earlier
public
inform
consent
obtain
particip
studi
approv
local
human
investig
committe
particip
hospit
receiv
placebo
studi
particip
present
clinic
suspicion
pneumonia
particip
sentinel
centr
hospit
one
outpati
clinic
underw
standard
clinic
evalu
includ
physic
radiolog
microbiolog
evalu
well
oropharyng
swab
urin
sampl
urinari
antigen
detect
oropharyng
swab
analys
singl
laboratori
univers
medic
centr
utrecht
netherland
presenc
human
virus
influenza
viru
b
respiratori
syncyti
viru
parainfluenza
viru
human
rhinoviru
metapneumoviru
coronaviru
bocaviru
adenoviru
use
quantit
realtim
pcr
roch
molecular
system
inc
pleasanton
ca
usa
nucleic
acid
isol
cdna
synthesi
pcr
perform
describ
loen
et
al
influenza
viru
b
parainfluenza
viru
parainfluenza
viru
test
stepwis
manner
first
test
posit
two
virus
follow
subtyp
subtyp
fail
episod
consid
nontyp
influenza
parainfluenza
urin
sampl
central
process
pfizer
vaccin
new
york
ny
usa
detect
pneumococc
urinari
antigen
use
aler
waltham
usa
serotyp
specif
urinari
antigen
detect
uad
assay
identifi
pneumococc
serotyp
includ
culturesd
either
steril
nonsteril
sitesdand
uad
assay
legionella
pneumophilia
collect
process
accord
local
practic
analys
two
differ
endpoint
definit
use
confirm
cap
suspect
pneumonia
confirm
cap
defin
episod
chest
xray
consist
pneumonia
see
supplementari
materi
appendix
detail
togeth
presenc
two
follow
clinic
criteria
cough
purul
sputum
temperatur
c
c
auscultatori
find
consist
pneumonia
leucocytosi
white
blood
cellslitr
band
creactiv
protein
three
time
upper
limit
normal
hypoxaemia
oxygen
pressur
mmhg
patient
breath
room
air
patient
suspect
pneumonia
individu
present
clinic
suspicion
pneumonia
particip
sentinel
centr
also
includ
confirm
cap
individu
symptom
onset
least
day
vaccin
includ
efficaci
analys
iacap
defin
confirm
cap
episod
influenza
viru
b
detect
oropharyng
swab
regardless
presenc
bacteri
pathogen
anoth
viral
pathogen
viral
associ
cap
defin
confirm
cap
virus
includ
influenza
viru
detect
oropharyng
swab
also
regardless
bacteri
pathogen
definit
appli
suspect
pneumonia
microbiolog
aetiolog
base
sampl
obtain
within
first
day
hospit
admiss
obtain
present
emerg
room
case
individu
admit
pathogen
consid
caus
cultur
blood
steril
site
case
uad
assay
posit
absenc
cultur
microorgan
blood
steril
site
uad
legionella
perform
accord
standard
care
practic
purpos
exploratori
analysi
consid
microorgan
cultur
sputum
caus
microbiolog
cultur
uad
assay
yield
caus
pathogen
perform
reason
collect
urin
sampl
systemat
collect
case
reason
collect
oropharyng
swab
therefor
urin
sampl
oropharyng
swab
collect
patient
assum
reason
would
similar
sampl
except
reason
urinespecif
eg
anuria
reason
report
individu
directli
admit
intens
care
unit
hospit
assum
sever
ill
admit
reason
miss
respect
pneumonia
sever
index
part
prespecifi
analysi
calcul
individu
data
prospect
collect
outsid
capita
studi
protocol
separ
case
record
form
part
etiocap
studi
season
influenza
vaccin
previou
yearda
report
individualdwa
record
determin
proport
confirm
cap
case
receiv
season
influenza
vaccin
previou
year
first
cap
episod
septemb
august
use
evalu
contribut
iacap
total
aetiolog
cap
per
year
per
season
proport
iacap
among
confirm
cap
episod
swab
avail
stratifi
year
septemb
august
base
day
admiss
evalu
vaccin
efficaci
first
episod
iacap
virusassoci
cap
evalu
two
virus
detect
one
influenza
viru
cap
episod
includ
efficaci
analys
coxregress
model
time
first
viral
episod
eg
iacap
use
determin
vaccin
efficaci
e
hr
correct
multipl
test
confid
interv
use
analys
perform
accord
intentiontotreat
principl
overal
proport
also
includ
follow
episod
also
present
calcul
pneumonia
sever
index
assum
miss
variabl
within
normal
rang
eg
normal
ph
normal
po
arteri
blood
ga
test
perform
descript
analys
pearson
chisquar
test
use
calcul
pvalu
categor
variabl
mannewhitney
u
test
use
continu
variabl
nonnorm
distribut
statist
program
ibm
spss
statist
version
ibm
corp
armonk
ny
usa
use
analys
individu
receiv
receiv
placebo
vaccin
mean
durat
follow
year
episod
suspect
pneumonia
identifi
particip
sentinel
centr
episod
fulfil
criteria
confirm
cap
fig
individu
oropharyng
swab
avail
fig
display
combin
avail
diagnost
method
individu
either
diagnost
method
ie
cultur
legionella
uad
pneumococc
uad
cultur
pneumococc
uad
avail
individu
meet
criteria
suspect
pneumonia
oropharyng
swab
avail
fig
oropharyng
swab
miss
confirm
cap
episod
equal
distribut
among
treatment
arm
reason
tabl
subject
without
swab
higher
pneumonia
sever
index
p
less
frequent
hospit
p
viru
detect
individu
confirm
cap
ten
two
virus
detect
see
supplementari
materi
tabl
among
confirm
cap
episod
swab
avail
viral
pathogen
detect
viralebacteri
coinfect
bacteri
caus
episod
caus
pathogen
detect
tabl
tabl
present
frequent
pathogen
patient
confirm
cap
stratifi
aetiolog
categori
treatment
arm
among
episod
influenza
viru
one
parainfluenza
virus
detect
five
nine
nontyp
swab
respect
overal
number
viru
detect
patient
confirm
cap
suspect
pneumonia
includ
confirm
cap
influenza
human
metapneumoviru
respiratori
syncyti
viru
rhinoviru
see
supplementari
materi
tabl
first
episod
iacap
among
confirm
cap
episod
arm
placebo
arm
result
vaccin
efficaci
ci
p
total
first
episod
virusassoci
cap
occur
vaccin
efficaci
ci
p
tabl
among
suspect
pneumonia
episod
signific
reduct
iacap
virusassoci
cap
could
demonstr
either
tabl
patient
oropharyng
swab
avail
viral
monoinfect
frequent
suspect
pneumonia
exclud
confirm
cap
patient
confirm
cap
p
contrast
bacteri
caus
frequent
occur
among
confirm
cap
case
n
among
individu
suspect
pneumonia
exclud
confirm
cap
n
p
aetiolog
categori
equal
spread
among
placebo
tabl
accumul
first
admiss
septemb
august
everi
studi
year
result
episod
confirm
cap
individu
influenza
statu
previou
year
known
receiv
season
influenza
vaccin
arm
placebo
arm
season
influenza
vaccin
also
report
iacap
episod
signific
differ
iacap
individu
without
season
influenza
vaccin
p
proport
season
influenza
vaccin
per
year
gradual
decreas
see
supplementari
materi
fig
annual
rate
iacap
among
confirm
cap
episod
swab
vari
season
season
fig
abl
detect
statist
signific
reduct
first
episod
iacap
virusassoci
cap
episod
among
elderli
vaccin
larg
doubleblind
random
control
trial
particip
high
slightli
decreas
annual
uptak
season
influenza
fig
diagram
avail
diagnost
method
individu
confirm
cap
oropharyng
swab
avail
n
abbrevi
use
cap
communityacquir
pneumonia
uad
urinari
antigen
detect
assay
cultur
either
steril
eg
blood
nonsteril
eg
sputum
sampl
avail
cultur
pneumococc
uad
either
convent
pneumococc
urinari
antigen
detect
assay
ie
binax
serotypespecif
urinari
antigen
detect
assay
pleas
note
diagram
exclud
patient
diagnost
method
avail
ie
oropharyng
swab
viral
analys
vaccin
low
overal
incid
iacap
proport
iacap
fluctuat
year
season
impact
vaccin
virusassoci
cap
adult
determin
children
vaccin
nineval
pcv
reduc
occurr
iacap
absenc
signific
reduct
current
studi
may
result
low
incid
detect
influenza
infect
given
observ
incid
placebo
group
minim
detect
effect
size
iacap
iasuspect
pneumonia
ie
effect
size
would
statist
signific
vaccin
efficaci
respect
influenza
viru
pneumonia
coinfect
common
among
children
adult
high
uptak
season
influenza
vaccin
studi
popul
observ
preval
iacap
current
studi
similar
report
larg
studi
detect
virus
pcr
adult
hospit
cap
studi
preval
influenza
viru
among
adult
cap
patient
vari
netherland
consult
influenzalik
ill
gener
practition
monitor
weekli
basi
influenza
season
incid
fluctuat
per
year
observ
dutch
influenzalik
ill
incid
pattern
though
resembl
observ
incid
pattern
studi
cohort
nation
level
influenzalik
ill
incid
highest
lowest
cohort
proport
iacap
highest
lowest
fig
probabl
result
differ
measur
use
incid
versu
proport
also
differ
patient
popul
studi
individu
visit
gener
practition
versu
patient
hospit
cap
differ
sever
domin
certain
influenza
strain
might
also
play
role
moreov
incid
influenzalik
ill
consult
cover
age
defin
aetiolog
studi
also
provid
insight
epidemiolog
respiratori
infect
associ
noninfluenza
virus
elderli
instanc
proport
episod
confirm
suspect
cap
associ
respiratori
syncyti
viru
detect
respiratori
sampl
respect
find
extend
previou
observ
low
incid
respiratori
syncyti
viru
among
sever
ill
patient
admit
intens
care
unit
respiratori
infect
strength
studi
random
doubleblind
design
sampl
size
standard
diagnost
method
diagnos
pneumonia
detect
virus
pcr
assay
wide
valid
consid
refer
standard
detect
respiratori
virus
weak
includ
miss
oropharyng
swab
confirm
episod
cap
swab
miss
frequent
individu
sever
ill
admit
due
random
doubleblind
design
unlik
miss
swab
influenc
observ
rel
effect
furthermor
studi
cohort
includ
rel
healthi
adult
immunodefici
individu
exclud
although
studi
particip
chronic
comorbid
develop
immunodefici
follow
find
may
lack
extern
valid
immunodefici
individu
generaliz
result
may
also
limit
countri
epidemiolog
influenza
pneumococc
diseas
lower
influenza
vaccin
uptak
statist
signific
vaccin
efficaci
vaccin
elderli
iacap
could
demonstr
studi
peopl
averag
durat
follow
year
yet
low
incid
iacap
clinic
relev
effect
rule
vaccin
recommend
adult
year
older
usa
sinc
septemb
observ
studi
implement
may
provid
evid
effect
pneumococc
conjug
vaccin
influenza
infect
author
complet
submit
icmj
form
disclosur
potenti
conflict
interest
mbon
receiv
research
grant
pfizer
sh
fc
mbol
cw
mbon
employ
univers
medic
centr
utrecht
cw
particip
pfizer
expert
meet
cw
sh
report
financi
support
pfizer
thesi
print
